Vetter Pharma sets up new subsidiary
Germany's Vetter Pharma-Fertigung GmbH has established a new subsidiary, Vetter Pharma International GmbH. With a scheduled launch date of April 1, VPI will be responsible for all the firm's sales, marketing and customer service activities on a worldwide level.
Peter Soelkner has been named managing director, and Oskar Gold will serve as vice president of the new entity. Headquarters will be in Ravensburg, Germany, and Vetter Pharma International USA will be located in Yardley, Pennsylvania.
Vetter is an independent international specialist in the aseptic filling of syringes, cartridges and vials. Based in Ravensburg, it also produces its own injection systems, such as the Vetter Lyo-Ject dual-chamber syringe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze